Report for: Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial

Title	Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial
Published in	Trials, March 2021
DOI	10.1186/s13063-021-05132-9
Pubmed ID	33750432
Authors	Benjamin Gaborit, Bernard Vanhove, Marie-Anne Vibet, Aurélie Le Thuaut, Karine Lacombe, Vincent Dubee, Florence Ader, Virginie Ferre, Eric Vicaut, Jéremie Orain, Morgane Le Bras, Anne Omnes, Laetitia Berly, Alexandra Jobert, Pascale Morineau-Le Houssine, Karine Botturi, Régis Josien, Laurent Flet, Nicolas Degauque, Sophie Brouard, Odile Duvaux, Alexandra Poinas, François Raffi

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.

Country	Count	As %
Poland	1	25%
Unknown	3	75%

Type	Count	As %
Members of the public	4	100%

Mendeley readers

The data shown below were compiled from readership statistics for 86 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Country	Count	As %
Unknown	86	100%

Readers by professional status	Count	As %
Researcher	11	13%
Student > Bachelor	10	12%
Student > Master	8	9%
Student > Ph. D. Student	5	6%
Librarian	4	5%
Other	5	6%
Unknown	43	50%

Readers by discipline	Count	As %
Medicine and Dentistry	18	21%
Nursing and Health Professions	7	8%
Pharmacology, Toxicology and Pharmaceutical Science	6	7%
Immunology and Microbiology	4	5%
Social Sciences	2	2%
Other	6	7%
Unknown	43	50%

Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial